tetano
Editor, Senior Moderator
J Infect Dis
. 2020 Jul 16;jiaa429.
doi: 10.1093/infdis/jiaa429. Online ahead of print.
Estimation Without Representation: Early Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Studies and the Path Forward
Bonnie E Shook-Sa[SUP] 1 [/SUP], Ross M Boyce[SUP] 2 [/SUP], Allison E Aiello[SUP] 3 4 [/SUP]
Affiliations
Abstract
The recent development and regulatory approval of a variety of serological assays indicating the presence of antibodies against severe acute respiratory syndrome coronavirus 2 has led to rapid and widespread implementation of seroprevalence studies. Accurate estimates of seroprevalence are needed to model transmission dynamics and estimate mortality rates. Furthermore, seroprevalence levels in a population help guide policy surrounding reopening efforts. The literature to date has focused heavily on issues surrounding the quality of seroprevalence tests and less on the sampling methods that ultimately drive the representativeness of resulting estimates. Seroprevalence studies based on convenience samples are being reported widely and extrapolated to larger populations for the estimation of total coronavirus disease 2019 (COVID-19) infections, comparisons of prevalence across geographic regions, and estimation of mortality rates. In this viewpoint, we discuss the pitfalls that can arise with the use of convenience samples and offer guidance for moving towards more representative and timely population estimates of COVID-19 seroprevalence.
Keywords: COVID-19; address-based sampling; convenience sampling; seroprevalence; transmission
. 2020 Jul 16;jiaa429.
doi: 10.1093/infdis/jiaa429. Online ahead of print.
Estimation Without Representation: Early Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Studies and the Path Forward
Bonnie E Shook-Sa[SUP] 1 [/SUP], Ross M Boyce[SUP] 2 [/SUP], Allison E Aiello[SUP] 3 4 [/SUP]
Affiliations
- PMID: 32750135
- DOI: 10.1093/infdis/jiaa429
Abstract
The recent development and regulatory approval of a variety of serological assays indicating the presence of antibodies against severe acute respiratory syndrome coronavirus 2 has led to rapid and widespread implementation of seroprevalence studies. Accurate estimates of seroprevalence are needed to model transmission dynamics and estimate mortality rates. Furthermore, seroprevalence levels in a population help guide policy surrounding reopening efforts. The literature to date has focused heavily on issues surrounding the quality of seroprevalence tests and less on the sampling methods that ultimately drive the representativeness of resulting estimates. Seroprevalence studies based on convenience samples are being reported widely and extrapolated to larger populations for the estimation of total coronavirus disease 2019 (COVID-19) infections, comparisons of prevalence across geographic regions, and estimation of mortality rates. In this viewpoint, we discuss the pitfalls that can arise with the use of convenience samples and offer guidance for moving towards more representative and timely population estimates of COVID-19 seroprevalence.
Keywords: COVID-19; address-based sampling; convenience sampling; seroprevalence; transmission